Pharmacogenetics and the immunogenicity of protein therapeutics

Journal of Interferon and Cytokine Research

Volumn 34, Issue 12, 2014, Pages 931-937

  Pandey, Gouri S ^a   Sauna, Zuben E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

CODON; GENETIC MARKER; GENETIC TRAIT; GENETIC VARIABILITY; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MISSENSE MUTATION; NONSENSE MUTATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROTEIN ENGINEERING; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 84918504398     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0136     Document Type: Review

References (40)

1. Aledort LM, Navickis RJ, Wilkes MM. 2011. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 9:2180-2192.
2. Astermark J, Lacroix-Desmazes S, Reding MT. 2008. Inhibitor development. Haemophilia 14 Suppl 3:36-42.
3. Bassani-Sternberg M, Barnea E, Beer I, Avivi I, Katz T, Admon A. 2010. Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A 107:18769-18776.
4. Boekhorst J, Lari GR, d'Oiron R, Costa JM, Novakova IR, Ala FA, Lavergne JM, VAN Heerde WL. 2008. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 14:729-735.
5. Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr ME, Jr. 2007. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 13:533-541.
6. Evans WE, Relling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
7. Fijnvandraat K, Turenhout EA, van Den Brink EN, ten Cate JW, van Mourik JA, Peters M, Voorberg J. 1997. The missense mutation Arg593- > Cys is related to antibody formation in a patient with mild hemophilia A. Blood 89:4371-4377.
8. Gilles JG, Lavend'homme R, Peerlinck K, Jacquemin MG, Hoylaerts M, Jorieux S, Mazurier C, Vermylen J, Saint-Remy JM. 1999. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb Haemost 82:40-45.
9. Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, Thompson AR, van HW, Boekhorst J, Miller CH, le CS, van der Bom JG. 2012. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119:2922-2934.
10. Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, Pratt KP. 2011. Haemophilia management: time to get personal? Haemophilia 17:721-728.
11. Iorio A, Marcucci M, Makris M. 2011. Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost 9:2176-2179.
12. Jacquemin M, Vantomme V, Buhot C, Lavend'homme R, Burny W, Demotte N, Chaux P, Peerlinck K, Vermylen J, Maillere B, van der Bruggen P, Saint-Remy JM. 2003. CD4(+) T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101:1351-1358.
13. Kalow W. 1956. Familial incidence of low pseudocholinesterase level. Lancet 271:576-577.
14. Krejsa C, Rogge M, Sadee W. 2006. Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov 5:507-521.
15. Lanzavecchia A, Reid PA, Watts C. 1992. Irreversible association of peptides with class II MHC molecules in living cells. Nature 357:249-252.
16. Lillicrap D. 2010. Improvements in factor concentrates. Curr Opin Hematol 17:393-397.
17. Mannucci PM, Tuddenham EGD. 2001. Medical progress - The hemophilias - From royal genes to gene therapy. New Engl J Med 344:1773-1779.
18. Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig HW. 2012. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 18:375-382.
19. Nielsen M, Lund O, Buus S, Lundegaard C. 2010. MHC class II epitope predictive algorithms. Immunology 130:319-328.
20. Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J. 1999. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 93:2267-2273.
21. Rathore AS, Winkle H. 2009. Quality by design for biopharmaceuticals. Nat Biotechnol 27:26-34.
22. Rosenberg AS. 2004. Risk-based approach to immunogenicity concerns of therapeutic protein products, part 2-Considering host specific and product specific factors impacting immunogenicity. BioPharm Int 17:34-42.
23. Rosenberg AS. 2005. A risk-based approach to immunogenicity concerns fo therapeutic protein products. BioPharm Int 18:32-36.
24. Rosenberg AS, Worobec A. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products Part 1 Considering consequences of the immune response to a protein. BioPharm Int 17:22-26.
25. Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, Sebring S, Mikaelsson M. 2001. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 85:93-100.
26. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. 1995. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 74:619-621.
27. Sauna ZE, Ameri A, Kim B, Yanover C, Viel KR, Rajalingam R, Cole SA, Howard TE. 2012a. Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective. J Thromb Haemost 10:1961-1965.
28. Sauna ZE, Pandey GS, Jain N, Mahmood I, Kimchi-Sarfaty C, Golding B. 2012b. Plasma derivatives: new products and new approaches. Biologicals 40:191-195.
29. Schwarz J, Astermark J, Menius ED, Carrington M, Donfield SM, Gomperts ED, Nelson GW, Oldenburg J, Pavlova A, Shapiro AD, Winkler CA, Berntorp E. 2013. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia 19:113-118.
30. Shankar G, Pendley C, Stein KE. 2007. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25:555-561.
31. Spear BB, Heath-Chiozzi M, Huff J. 2001. Clinical application of pharmacogenetics. Trends Mol Med 7:201-204.
32. Steinitz KN, van Helden PM, Binder B, Wraith DC, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Weiller M, Lubich C, de la Rosa M, Schwarz HP, Reipert BM. 2012. CD4 + T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1∗1501 mice. Blood 119:4073-4082.
33. Vidal M, Cusick ME, Barabasi AL. 2011. Interactome networks and human disease. Cell 144:986-998.
34. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. 2009. Inhibitors of Factor VIII in Black Patients with Hemophilia. New Engl J Med 360:1618-1627.
35. Viel KR, Machiah DK, Warren DM, Khachidze M, Buil A, Fernstrom K, Souto JC, Peralta JM, Smith T, Blangero J, Porter S, Warren ST, Fontcuberta J, Soria JM, Flanders WD, Almasy L, Howard TE. 2007. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 109:3713-3724.
36. Walsh G. 2010. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917-924.
37. Wang JH, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A, Shores E, Rosenberg A. 2008a. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 26:901-908.
38. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008b. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4:e1000048.
39. Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE. 2011. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol 29:870-873.
40. Zhang AH, Skupsky J, Scott DW. 2009. Factor VIII Inhibitors: risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol 37:114-124.